Binds Retrovirus Or Component Or Product Thereof (e.g., Hiv, Lav, Htlv, Etc.) Patents (Class 530/388.35)
  • Publication number: 20150044137
    Abstract: Neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Inventors: John R. Mascola, Rebecca M. Lynch, Xueling Wu, Mark Connors, Tongqing Zhou, Joseph Casazza, Peter D. Kwong
  • Patent number: 8871899
    Abstract: The present invention relates to a peptide having one or more stable, internally-constrained HBS ?-helices, where the peptide mimics at least a portion of a class I C-peptide helix or at least a portion of a class I N-peptide helix of a viral (e.g., HIV-I) coiled-coil assembly. Methods of inhibiting viral infectivity of a subject by administering these peptides are also disclosed.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: October 28, 2014
    Assignee: New York University
    Inventors: Deyun Wang, Paramjit Arora
  • Publication number: 20140234332
    Abstract: The invention provides a novel strain of HIV-2 capable of causing immunodeficiency. The invention also provides compositions comprising the nucleic acids and polypeptides characteristic of this HIV-2 virus, antibodies specific for this HIV-2 virus, methods of using these compositions, and methods of detecting HIV-2 virus.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Tulane University Health and Sciences Center
    Inventors: Stephen M. Smith, Preston A. Marx, JR.
  • Publication number: 20140205612
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: July 24, 2014
    Applicants: THERACLONE SCIENCES, INC., INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Patent number: 8747855
    Abstract: Provided are antibodies comprising an antigen recognition domain capable of binding an MHC molecule being complexed with a human immunodeficiency virus (HIV) peptide, wherein the antibody does not bind the MHC molecule in an absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC molecule. Also provided are methods of using same for diagnosing HIV infection and treating AIDS.
    Type: Grant
    Filed: April 5, 2009
    Date of Patent: June 10, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Yoram Reiter, Maya Haus-Cohen
  • Patent number: 8722861
    Abstract: The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies: (a) an antibody having the amino acid sequence shown in SEQ ID NO: 1 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 2 as the amino acid sequence of a L chain variable region (VL); and (b) an antibody having the amino acid sequence shown in SEQ ID NO: 3 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 4 as the amino acid sequence of a L chain variable region (VL).
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: May 13, 2014
    Assignee: Kumamoto University
    Inventors: Shuzo Matsushita, Kazuhisa Yoshimura
  • Publication number: 20140099324
    Abstract: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
    Type: Application
    Filed: March 18, 2013
    Publication date: April 10, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Feng WANG-JOHANNING
  • Patent number: 8673307
    Abstract: Broad neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV, especially the preparation and use of highly neutralizing antibodies directed to HIV gp120 envelope protein, in the vaccination and treatment of HIV-infected patients.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: March 18, 2014
    Assignee: The Rockefeller University
    Inventors: Michel C. Nussenzweig, Johannes Scheid, John Pietzsch
  • Patent number: 8647818
    Abstract: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: February 11, 2014
    Assignees: UAB Research Foundation, University of Alabama—Birmingham, The United States of America, as represented by the Secretary, Department of Health and Human Services (Hereinafter the Government) Office of Technology Transfer, National Institutes of Health
    Inventors: George M. Shaw, Beatrice H. Hahn, Frederic Bibollet-Ruche, Peter D. Kwong
  • Patent number: 8637234
    Abstract: Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: January 28, 2014
    Assignees: UAB Research Foundation, The Administrators of Tulane Educational Fund, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: George M. Shaw, James E. Robinson, Frederic Bibollet-Ruche, Julie M. Decker, Beatrice H. Hahn, Peter D. Kwong
  • Patent number: 8541553
    Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: September 24, 2013
    Assignee: Baxter Healthcare SA
    Inventors: Johannes Humer, Bernd Mayer, Thomas Muster, Andrea Waltenberger
  • Patent number: 8475799
    Abstract: The invention relates to isolated monoclonal antibodies which specifically bind to the C-terminal heptad repeat region of gp41 (HR2) and neutralize an HIV-1 primary isolate.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: July 2, 2013
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventor: Abraham Pinter
  • Publication number: 20130130233
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Application
    Filed: October 9, 2012
    Publication date: May 23, 2013
    Applicant: ABBOTT LABORATORIES
    Inventor: Abbott Laboratories
  • Publication number: 20130028908
    Abstract: Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 31, 2013
    Applicant: Medestea Research & Production S.p.A.
    Inventors: Arnaldo Caruso, Giulia Federica Merizzi, Antonio Soleti
  • Publication number: 20120269821
    Abstract: The present invention relates, in general, to HIV-1 antibodies and, in particular, to broadly neutralizing HIV-1 antibodies that target the gp41 membrane-proximal external region (MPER).
    Type: Application
    Filed: December 8, 2011
    Publication date: October 25, 2012
    Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, Lynn Morris, Salim S. Abdool Karim
  • Patent number: 8282926
    Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: October 9, 2012
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8246957
    Abstract: Disclosed are monoclonal antibodies and antibody fragments which recognize antigens encoded by HERV DNA sequences, and methods for production, including recombinant antibody fragments derived from lymphoid cells of lupus patients that make antibodies which neutralize HIV.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: August 21, 2012
    Inventor: Sudhir Paul
  • Publication number: 20120100632
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Application
    Filed: February 9, 2011
    Publication date: April 26, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 8110192
    Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: February 7, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Mei-Yun Zhang
  • Publication number: 20110236393
    Abstract: The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter.
    Type: Application
    Filed: November 4, 2009
    Publication date: September 29, 2011
    Inventors: Kwan-ki Hwang, Micah Luftig
  • Publication number: 20110223615
    Abstract: The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).
    Type: Application
    Filed: November 12, 2009
    Publication date: September 15, 2011
    Applicant: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: George K. Lewis, Yongjun Guan
  • Publication number: 20110177090
    Abstract: The present invention provides compositions and methods for the specific and sensitive detection and characterization of anti-carbohydrate antibodies against immunogenic sugar moieties on microbes and abnormal cells and anti-HIV-1 protein antibodies for the development of diagnostic, prophylactic and therapeutic strategies against diseases inflicted by cancer cells or microbial pathogens.
    Type: Application
    Filed: January 19, 2011
    Publication date: July 21, 2011
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Denong Wang, Leonore A. Herzenberg
  • Publication number: 20110142847
    Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 16, 2011
    Applicants: Panacos Pharmaceuticals, Inc., GOVERNMENT OF THE U.S., REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Carl T. Wild, Carol D. Weiss
  • Publication number: 20110044994
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Application
    Filed: March 17, 2010
    Publication date: February 24, 2011
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
  • Publication number: 20110044995
    Abstract: The present invention provides a monoclonal antibody that recognizes the V3 loop of the envelope glycoprotein gp120 of AIDS virus, which is any one selected from the following antibodies: (a) an antibody having the amino acid sequence shown in SEQ ID NO: 1 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 2 as the amino acid sequence of a L chain variable region (VL); and (b) an antibody having the amino acid sequence shown in SEQ ID NO: 3 as the amino acid sequence of a H chain variable region (VH), and having the amino acid sequence shown in SEQ ID NO: 4 as the amino acid sequence of a L chain variable region (VL).
    Type: Application
    Filed: November 19, 2008
    Publication date: February 24, 2011
    Applicant: KUMAMOTO UNIVERSITY
    Inventors: Shuzo Matsushita, Kazuhisa Youshimura
  • Publication number: 20100303858
    Abstract: The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a specific humoral immune response. Application for the preparation of vaccinal and pharmaceutical composition.
    Type: Application
    Filed: November 28, 2006
    Publication date: December 2, 2010
    Inventors: Francisco Veas, Claudio Vita, Mireille C. Sauvage, Fabio Vita, Elena Vita, Loic Martin, Dorothy Bray, Kadija Benlhassan-Chahour
  • Patent number: 7759467
    Abstract: A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: July 20, 2010
    Assignee: Indiana University Research and Technology Corporation
    Inventors: David A Williams, Vikram P Patel
  • Patent number: 7700726
    Abstract: Disclosed is a novel HIV gene comprising a set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat. The genes encode a set of antisense proteins, (HAPs) as well as smaller proteins, related to, and containing structural motif resembling that of chemokine proteins. Depending upon the ribosomal frameshift, a plurality of proteins may be translated from the antisense RNA. The smaller proteins have similarity with chemokine SDF-1 and may play a role as a cofactor with gp120 in the binding to and entry of HIV to a target cell.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: April 20, 2010
    Inventor: Linda B. Ludwig
  • Patent number: 7700725
    Abstract: Disclosed is a novel HIV gene comprising a set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat. The genes encode a set of antisense proteins, (HAPs) as well as smaller proteins, related to, and containing structural motif resembling that of chemokine proteins. Depending upon the ribosomal frameshift, a plurality of proteins may be translated from the antisense RNA. The smaller proteins have similarity with chemokine SDF-1 and may play a role as a cofactor with gp120 in the binding to and entry of HIV to a target cell.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: April 20, 2010
    Inventor: Linda B. Ludwig
  • Patent number: 7667006
    Abstract: The present invention aims at providing a high affinity anti-HIV antibody. According to the present invention, there are provided an antibody or a fragment thereof that binds to the gp12 glycoprotein of HIV and has a dissociation constant (KD) value of 1.0×10?9 (M) or less; a pharmaceutical composition comprising the antibody or fragment thereof; and a method of producing an anti-HIV antibody or a fragment thereof, comprising immunizing a GANP transgenic non-human mammal or a progeny thereof with a polypeptide consisting of the amino acid sequence as shown in SEQ ID NO: 6 as an antigen and collecting the antibody from the resultant mammal or progeny.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: February 23, 2010
    Assignee: Kumamoto Technology and Industry Foundation
    Inventors: Nobuo Sakaguchi, Kazuhiko Kuwahara, Chiemi Minoda
  • Patent number: 7625566
    Abstract: The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: December 1, 2009
    Assignee: Polymun Scientific Immunbiologische Forschung GmbH
    Inventors: Renate Kunert, Robert Weik, Gabriela Stiegler, Hermann Katinger
  • Patent number: 7595049
    Abstract: The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: September 29, 2009
    Assignee: Polymun Scientific Immunobiologische Forschung GmbH
    Inventors: Gabriela Stiegler, Renate Kunert, Hermann Katinger
  • Publication number: 20090191216
    Abstract: The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO 1 or a functional analogue thereof.
    Type: Application
    Filed: November 1, 2007
    Publication date: July 30, 2009
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Morgane Bomsel, Daniela Tudor
  • Patent number: 7566451
    Abstract: The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: July 28, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Mei-Yun Zhang
  • Patent number: 7531640
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: May 12, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 7531641
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: May 12, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 7531642
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: May 12, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 7531639
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: May 12, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 7531638
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: May 12, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 7528238
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: September 14, 2004
    Date of Patent: May 5, 2009
    Assignee: Abbott Laboratories, Inc.
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Publication number: 20080293036
    Abstract: The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided.
    Type: Application
    Filed: June 22, 2005
    Publication date: November 27, 2008
    Inventors: Jeffrey B. Kopp, Terence M. Phillips, Ulrich Schubert, John Yewell
  • Patent number: 7326416
    Abstract: Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treating the cells with the above peptides or vectors. Other methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by inhibiting production of INI1/hSNF5 are provided. Additionally, methods of determining whether a test compound inhibits HIV-1 virion production in a mammalian cell, or spread of the HIV-1 to another cell, are provided. Those methods comprise determining whether the test compound inhibits the production of INI1/hSNF5 or disrupts the interaction of HIV-1 integrase with INI1/hSNF5.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: February 5, 2008
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventor: Ganjam V. Kalpana
  • Patent number: 7223844
    Abstract: The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody fragments. The invention also features nucleic acids encoding the antibodies or antibody fragments, pharmaceutical compositions comprising the nucleic acids encoding the antibodies or antibody fragments, vectors comprising the nucleic acids, and cells comprising the vectors. The invention further features methods of identifying antibodies or antibody fragments with broadly neutralizing activity against HIV. The invention also features methods of inhibiting HIV entry into cells and methods of inhibiting replication of HIV in mammals, using the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: May 29, 2007
    Assignees: United States of America, Represented by the Secretary, Department of Health and Human Services, Scripps Research Institute
    Inventors: Dimiter S. Dimitrov, Maxime Moulard, Xiadong Xiao, Yuuei Shu, Sanjay K. Phogat, Mei-Yun Zhang, Dennis Burton
  • Patent number: 7189826
    Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: March 13, 2007
    Assignee: Institute for Human Genetics and Biochemistry
    Inventor: Toby C. Rodman
  • Patent number: 7122638
    Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: October 17, 2006
    Assignee: The Institute for Human Genetics and Biochemistry
    Inventor: Toby C. Rodman
  • Patent number: 7056735
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: June 6, 2006
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Patent number: 7041293
    Abstract: The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
  • Patent number: 7033593
    Abstract: The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: April 25, 2006
    Assignee: Duke University
    Inventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
  • Patent number: 7008622
    Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain the antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: March 7, 2006
    Assignee: Thymon, L.L.C.
    Inventor: Gideon Goldstein
  • Patent number: 6908734
    Abstract: This invention provides a compound comprising the structure: ??YDINYYTSE?? wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents an isoleucine; and each N represents an asparagine; wherein ? represents from 0 to 9 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the I at position 9 and extending therefrom in the amino terminal direction; wherein ? represents from 0 to 13 amino acids, with the proviso that if there are more than 2 amino acids, they are joined by peptide bonds in consecutive order and have a sequence identical to the sequence set forth in SEQ ID NO: 1 beginning with the P at position 19 and extending therefrom in the carboxy terminal direction; wherein ? represents an amino group or an acetylated amino
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: June 21, 2005
    Assignees: Progenics Pharmaceuticals, Inc., Aaron Diamond AIDS Research Centre
    Inventors: Tatjana Dragic, William C. Olson